Determination and Pharmacokinetic Study of Gefitinib in Rat Plasma by a Simple UPLC-MS/MS Method

被引：0

作者：

Li, Rui-fang ^{[1
]}

Chen, Jie-zhong ^{[2
]}

Sun, Wen-zhe ^{[1
]}

Li, Meng-ke ^{[1
]}

Sun, Ke ^{[1
]}

Wang, Jian-gang ^{[1
]}

机构：

[1] Henan Univ Sci & Technol, Coll Med, Luoyang 471003, Henan, Peoples R China

[2] Jiyuan Vocat & Tech Coll, Dept Nursing, Jiyuan 454650, Henan, Peoples R China

来源：

LATIN AMERICAN JOURNAL OF PHARMACY | 2015年 / 34卷 / 09期

关键词：

gefitinib; pharmacokinetic; rat plasma; UPLC-MS/MS; CELL LUNG-CANCER; TANDEM MASS-SPECTROMETRY; GROWTH-FACTOR RECEPTOR; SIMULTANEOUS QUANTIFICATION; ERLOTINIB; INHIBITOR; EFFICACY; IMATINIB; MUTATION; THERAPY;

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

In this study, a simple, rapid and sensitive ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method is described for determination of gefitinib in rat plasma samples using pirfenidone as the internal standard (IS) from pharmacokinetic assays. Sample preparation was accomplished through a simple protein precipitation with acetonitrile, and chromatographic separation was performed on an Acquity BEH C18 column (2.1 mm x 50 mm, 1.7 mu m) with gradient profile at a flow of 0.4 mL/min. The linearity of this method was found to be within the concentration range of 10-2000 ng/mL for gefitinib in rat plasma. Only 3.0 min was needed for an analytical run. The method was applied to a pharmacokinetic study after oral administration of 25 mg/kg gefitinib in rats.

引用

页码：1749 / 1753

页数：5

共 15 条

[1] Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS [J].

Bouchet, Stephane ;

Chauzit, Emmanuelle ;

Ducint, Dominique ;

Castaing, Nadege ;

Canal-Raffin, Mireille ;

Moore, Nicholas ;

Titier, Karine ;

Molimard, Mathieu .

CLINICA CHIMICA ACTA, 2011, 412 (11-12) :1060-1067

[2] Simultaneous Quantification of Erlotinib, Gefitinib, and Imatinib in Human Plasma by Liquid Chromatography Tandem Mass Spectrometry [J].

Chahbouni, A. ;

den Burger, J. C. G. ;

Vos, R. M. ;

Sinjewel, A. ;

Wilhelm, A. J. .

THERAPEUTIC DRUG MONITORING, 2009, 31 (06) :683-687

[3] A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma [J].

Faivre, Lionel ;

Gomo, Charline ;

Mir, Olivier ;

Taieb, Fabrice ;

Schoemann-Thomas, Audrey ;

Ropert, Stanislas ;

Vidal, Michel ;

Dusser, Daniel ;

Dauphin, Alain ;

Goldwasser, Francois ;

Blanchet, Benoit .

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2011, 879 (23) :2345-2350

[4] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].

Fukuoka, M ;

Yano, S ;

Giaccone, G ;

Tamura, T ;

Nakagawa, K ;

Douillard, JY ;

Nishiwaki, Y ;

Vansteenkiste, J ;

Kudoh, S ;

Rischin, D ;

Eek, R ;

Horai, T ;

Noda, K ;

Takata, I ;

Smit, E ;

Averbuch, S ;

Macleod, A ;

Feyereislova, A ;

Dong, RP ;

Baselga, J .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246

[5] Comparison of the Efficacy of Gefitinib in Patients with Non-Small Cell Lung Cancer according to the Type of Epidermal Growth Factor Receptor Mutation [J].

Igawa, Satoshi ;

Kasajima, Masashi ;

Ishihara, Mikiko ;

Kimura, Michiko ;

Hiyoshi, Yasuhiro ;

Asakuma, Maiko ;

Otani, Sakiko ;

Katono, Ken ;

Sasaki, Jiichiro ;

Masuda, Noriyuki .

ONCOLOGY, 2014, 87 (04) :215-223

[6] Outcomes of patients with advanced non-small cell tung cancer treated with gefitinib (ZD1839, 'Iressa') on an expanded access study [J].

Jänne, PA ;

Gurubhagavatula, S ;

Yeap, BY ;

Lucca, J ;

Ostler, P ;

Skarin, AT ;

Fidias, P ;

Lynch, TJ ;

Johnson, BE .

LUNG CANCER, 2004, 44 (02) :221-230

[7] Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - A randomized trial [J].

Kris, MG ;

Natale, RB ;

Herbst, RS ;

Lynch, TJ ;

Prager, D ;

Belani, CP ;

Schiller, JH ;

Kelly, K ;

Spiridonidis, H ;

Sandler, A ;

Albain, KS ;

Cella, D ;

Wolf, MK ;

Averbuch, SD ;

Ochs, JJ ;

Kay, AC .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (16) :2149-2158

[8] Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry [J].

Lankheet, N. A. G. ;

Hillebrand, M. J. X. ;

Rosing, H. ;

Schellens, J. H. M. ;

Beijnen, J. H. ;

Huitema, A. D. R. .

BIOMEDICAL CHROMATOGRAPHY, 2013, 27 (04) :466-476

[9] Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers [J].

Lee, DH ;

Han, JY ;

Lee, HG ;

Lee, JJ ;

Lee, EK ;

Kim, HY ;

Kim, HK ;

Hong, EK ;

Lee, JS .

CLINICAL CANCER RESEARCH, 2005, 11 (08) :3032-3037

[10] Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. [J].

Maemondo, Makoto ;

Inoue, Akira ;

Kobayashi, Kunihiko ;

Sugawara, Shunichi ;

Oizumi, Satoshi ;

Isobe, Hiroshi ;

Gemma, Akihiko ;

Harada, Masao ;

Yoshizawa, Hirohisa ;

Kinoshita, Ichiro ;

Fujita, Yuka ;

Okinaga, Shoji ;

Hirano, Haruto ;

Yoshimori, Kozo ;

Harada, Toshiyuki ;

Ogura, Takashi ;

Ando, Masahiro ;

Miyazawa, Hitoshi ;

Tanaka, Tomoaki ;

Saijo, Yasuo ;

Hagiwara, Koichi ;

Morita, Satoshi ;

Nukiwa, Toshihiro .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (25) :2380-2388

← 1 2 →